{
    "id": "3591a776-8385-d203-e063-6294a90ae759",
    "indications": "omeprazole proton pump inhibitor ( ppi ) indicated : • treatment active duodenal ulcer adults ( 1.1 ) • eradication helicobacter pylori reduce risk duodenal ulcer recurrence adults ( 1.2 ) • treatment active benign gastric ulcer adults ( 1.3 ) • treatment symptomatic gastroesophageal reflux disease ( gerd ) patients 2 years age older ( 1.4 ) • maintenance healing ee due acid-mediated gerd patients 2 years age older ( 1.6 ) • pathologic hypersecretory conditions adults ( 1.7 )",
    "contraindications": "indication recommended adult ( 2.1 ) pediatric ( 2.2 ) treatment active duodenal ulcer 20 mg daily 4 weeks ; patients may require additional 4 weeks ( 2.1 ) h. pylori eradication reduce risk duodenal ulcer recurrence triple therapy : omeprazole delayed-release capsules amoxicillin clarithromycin 20 mg 1000 mg 500 mg twice daily 10 days ( 2.1 ) * dual therapy : omeprazole delayed-release capsules clarithromycin 40 mg daily 14 days * * 500 mg three times daily 14 days ( 2.1 ) active benign gastric ulcer 40 mg daily 4 8 weeks ( 2.1 ) symptomatic gerd 20 mg daily 4 weeks ( 2.1 ) full prescribing information weight based dosing pediatric patients 2 years age older ( 2.2 ) ee due acid-mediated gerd 20 mg daily 4 8 weeks ( 2.1 ) * * * maintenance healing ee due acid-mediated gerd 20 mg daily ( 2.1 ) * * * * full prescribing information weight based dosing pediatric patients 2 years age older ( 2.2 ) pathological hypersecretory conditions starting dose 60 mg daily ( varies individual patient , full prescribing information ) long clinically indicated ( 2.1 ) * ulcer present , continue omeprazole delayed-release capsules 20 mg daily additional 18 days . * * ulcer present , continue omeprazole delayed-release capsules 20 mg daily additional 14 days . * * * additional 4 weeks treatment may given response ; recurrence additional 4 8 week courses may considered . * * * * studied 12 months . reduce 10 mg daily patients hepatic impairment ( child-pugh class , b , c ) asian patients ( 8.6 , 8.7 )",
    "warningsAndPrecautions": "omeprazole delayed-release capsules , usp 10 mg off-white pale yellow , elliptical spherical pellets filled size ‘ 3 ’ hard gelatin capsules opaque lavender coloured cap opaque yellow coloured body , imprinted cap body ‘ r157 ’ black ink . capsules supplied bottles 14. bottles 14 ndc 42708-158-14 storage store omeprazole delayed-release capsules tight container protected light moisture . store 20° 25°c ( 68° 77°f ) [ usp controlled room temperature ] .",
    "adverseReactions": "• omeprazole delayed-release capsules contraindicated patients known hypersensitivity including anaphylaxis formulation substituted benzimidazole . hypersensitivity may include anaphylaxis , anaphylactic shock , angioedema , bronchospasm , acute tubulointerstitial nephritis , urticaria [ ( 5.2 ) , ( 6 ) ] . • proton pump inhibitors ( ppis ) , including omeprazole , contraindicated patients receiving rilpivirine-containing products [ ( 7 ) ] . • information antibacterial agents ( clarithromycin amoxicillin ) indicated combination omeprazole , refer section package inserts .",
    "ingredients": [
        {
            "name": "CROSPOVIDONE",
            "code": "68401960MK"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "MEGLUMINE",
            "code": "6HG8UB2MUY"
        },
        {
            "name": "METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A",
            "code": "NX76LV5T8J"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "POLOXAMER 407",
            "code": "TUF2IVW3M2"
        },
        {
            "name": "POVIDONE",
            "code": "FZ989GH94E"
        },
        {
            "name": "TRIETHYL CITRATE",
            "code": "8Z96QXD6UM"
        },
        {
            "name": "D&C RED NO. 28",
            "code": "767IP0Y5NH"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "GELATIN",
            "code": "2G86QN327L"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "BUTYL ALCOHOL",
            "code": "8PJ61P6TS3"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "D&C YELLOW NO. 10 ALUMINUM LAKE",
            "code": "CQ3XH3DET6"
        },
        {
            "name": "FD&C BLUE NO. 1 ALUMINUM LAKE",
            "code": "J9EQA3S2JM"
        },
        {
            "name": "FD&C BLUE NO. 2--ALUMINUM LAKE",
            "code": "4AQJ3LG584"
        },
        {
            "name": "OMEPRAZOLE",
            "code": "KG60484QX9"
        }
    ],
    "organization": "QPharma, Inc.",
    "name": "Omeprazole",
    "effectiveTime": "20250513",
    "indications_original": "Omeprazole is a proton pump inhibitor (PPI) indicated for the: • Treatment of active duodenal ulcer in adults (1.1) • Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer recurrence in adults (1.2) • Treatment of active benign gastric ulcer in adults (1.3) • Treatment of symptomatic gastroesophageal reflux disease (GERD) in patients 2 years of age and older (1.4) • Maintenance of healing of EE due to acid-mediated GERD in patients 2 years of age and older (1.6) • Pathologic hypersecretory conditions in adults (1.7)",
    "contraindications_original": "Indication Recommended Adult (2.1) and Pediatric Dosage (2.2) Treatment of Active Duodenal Ulcer 20 mg once daily for 4 weeks; some patients may require an additional 4 weeks (2.1) H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Triple Therapy: Omeprazole delayed-release capsules Amoxicillin Clarithromycin 20 mg 1000 mg 500 mg Each drug twice daily for 10 days (2.1) * Dual Therapy: Omeprazole delayed-release capsules Clarithromycin 40 mg once daily for 14 days** 500 mg three times daily for 14 days (2.1) Active Benign Gastric Ulcer 40 mg once daily for 4 to 8 weeks (2.1) Symptomatic GERD 20 mg once daily for up to 4 weeks (2.1) See full prescribing information for weight based dosing in pediatric patients 2 years of age and older (2.2) EE due to Acid-Mediated GERD 20 mg once daily for 4 to 8 weeks (2.1) *** Maintenance of Healing of EE due to Acid-Mediated GERD 20 mg once daily (2.1) **** See full prescribing information for weight based dosing in pediatric patients 2 years of age and older (2.2) Pathological Hypersecretory Conditions Starting dose is 60 mg once daily (varies with individual patient, see full prescribing information) as long as clinically indicated (2.1) * if ulcer present, continue omeprazole delayed-release capsules 20 mg once daily for an additional 18 days. ** if ulcer present, continue omeprazole delayed-release capsules 20 mg once daily for an additional 14 days. *** an additional 4 weeks of treatment may be given if no response; if recurrence additional 4 to 8 week courses may be considered. **** studied for 12 months. Reduce the dosage to 10 mg once daily for patients with hepatic impairment (Child-Pugh Class A, B, or C) and Asian patients ( 8.6 , 8.7 )",
    "warningsAndPrecautions_original": "Omeprazole delayed-release capsules, USP 10 mg are off-white to pale yellow, elliptical to spherical pellets filled in size ‘3’ hard gelatin capsules with opaque lavender coloured cap and opaque yellow coloured body, imprinted on cap \n  \n                  \n                  and on body ‘R157’ with black ink. The capsules are supplied in bottles of 14.\n                  Bottles of 14 NDC 42708-158-14\n                  Storage\n                  Store omeprazole delayed-release capsules in a tight container protected from light and moisture.\n                  Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].",
    "adverseReactions_original": "• Omeprazole delayed-release capsules are contraindicated in patients with known hypersensitivity reactions including anaphylaxis to the formulation or any substituted benzimidazole. Hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute tubulointerstitial nephritis, and urticaria [see Warnings and Precautions (\n \n  5.2), Adverse Reactions\n \n  (\n                     6\n                     )].\n\n \n                  • Proton pump inhibitors (PPIs), including omeprazole, are contraindicated in patients receiving rilpivirine-containing products [see Drug Interactions\n \n  \n                     (7)].\n\n \n                  • For information about contraindications of antibacterial agents (clarithromycin and amoxicillin) indicated in combination with omeprazole, refer to the CONTRAINDICATIONS section of their package inserts."
}